Analysts Set ADMA Biologics Inc (ADMA) Target Price at $11.58

Share on StockTwits

ADMA Biologics Inc (NASDAQ:ADMA) has been given an average rating of “Buy” by the eight brokerages that are currently covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $11.58.

Several analysts have issued reports on ADMA shares. Oppenheimer set a $13.00 price target on ADMA Biologics and gave the company a “buy” rating in a report on Monday, August 13th. BidaskClub raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd. Chardan Capital started coverage on ADMA Biologics in a report on Monday, July 30th. They set a “buy” rating and a $10.00 price target for the company. ValuEngine raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Thursday, July 26th. Finally, Maxim Group boosted their price target on ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, July 26th.

ADMA Biologics stock opened at $5.26 on Wednesday. The firm has a market cap of $266.97 million, a P/E ratio of -2.75 and a beta of 2.28. The company has a debt-to-equity ratio of 0.79, a current ratio of 10.65 and a quick ratio of 8.88. ADMA Biologics has a one year low of $2.10 and a one year high of $6.96.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.02). The firm had revenue of $4.23 million for the quarter, compared to analysts’ expectations of $5.39 million. ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 89.78%. As a group, research analysts anticipate that ADMA Biologics will post -1.36 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its holdings in ADMA Biologics by 54.7% during the third quarter. JPMorgan Chase & Co. now owns 228,999 shares of the biotechnology company’s stock valued at $1,422,000 after purchasing an additional 81,003 shares during the period. Northern Trust Corp grew its holdings in ADMA Biologics by 618.2% during the second quarter. Northern Trust Corp now owns 209,313 shares of the biotechnology company’s stock valued at $944,000 after purchasing an additional 180,170 shares during the period. 683 Capital Management LLC grew its holdings in ADMA Biologics by 9.9% during the second quarter. 683 Capital Management LLC now owns 885,000 shares of the biotechnology company’s stock valued at $3,991,000 after purchasing an additional 80,000 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of ADMA Biologics by 188.0% in the second quarter. Bank of New York Mellon Corp now owns 54,828 shares of the biotechnology company’s stock worth $247,000 after acquiring an additional 35,791 shares during the period. Finally, Ardsley Advisory Partners bought a new position in shares of ADMA Biologics in the second quarter worth about $361,000. 55.07% of the stock is owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Story: Diversification in Investing

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply